What does the Expedited Review of IND aim to achieve?

The Expedited Review of Investigational New Drugs (IND) is specifically designed to focus on facilitating the development and approval of new therapies that address unmet medical needs, particularly for serious or life-threatening conditions. This program aims to accelerate the availability of essential drugs by prioritizing review processes and enhancing interaction between the drug sponsors and the regulatory body.

This expedited process recognizes the urgency of bringing new treatments to market when existing therapies may either be inadequate or non-existent for certain serious health issues. It allows for a more efficient evaluation without compromising the safety or efficacy standards that must be met before a drug can receive marketing approval. By doing so, the Expedited Review helps to ensure that patients who have limited options can access potentially life-saving treatments faster than they would under traditional review processes.